drugset / Trial / NCT01531075

Hepatitis B Vaccine in Patients With Inflammatory Bowel Disease

NCT01531075

Completed 91 enrolled Soroka University Medical Center
RandomizedParallel-groupOpen-labelPrevention

Summary

The objective is to assess the efficacy of Hepatitis B Virus vaccination in a population of IBD patients treated with immunosuppressive medications.

Timeline

Start
2012-04
Primary completion
2015-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Engerix-B Vaccine 20 ug
Subject Engerix-B Vaccine 1 ml
Subject Sci-B-Vac Vaccine 10 ug/ml
Subject Sci-B-Vac Vaccine 1 ml